Immuneering Corporation (IMRX) Financial Analysis & Valuation | Quarter Chart
Immuneering Corporation (IMRX)
IMRXPrice: $5.45
Fair Value: 🔒
🔒score
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by m... more
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience produ... more
Description
Shares
| Market Cap | $197.85M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Benjamin J. Zeskind |
| IPO Date | 2021-07-30 | CAGR | — |
| Employees | 54 | Website | immuneering.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
IMRX chart loading...
Fundamentals
Technicals
| Enterprise Value | $304.54M | P/E Ratio | -3.04 |
| Forward P/E | -3.86 | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 1.91 |
| P/CF Ratio | -8.28 | P/FCF Ratio | -4.66 |
| EPS | $-1.79 | EPS Growth 1Y | -32.02% |
| EPS Growth 3Y | -26.2% | EPS Growth 5Y | 8.66% |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -0.43% | ROA | -0.24% |
| ROCE | -267.57% | Current Ratio | 17.5 |
| Quick Ratio | 17.5 | Cash Ratio | 12.77 |
| Debt/Equity | 0.02 | Interest Coverage | — |
| Altman Z Score | 6.78 | Piotroski Score | 2 |